LOBE SCIENCES LTD (LOBEF)
LOBEF moved a median of 0.00% 30 minutes after news, and +2.34% by the close. How LOBEF actually reacts to news — the realized, point-in-time move the market made, measured across 50 labeled events over the last three years with zero look-ahead.
LOBEF’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 17% | 47 |
| 30-min | 0.00% | 30% | 47 |
| 60-min | 0.00% | 40% | 47 |
| to close | +2.34% | 58% | 45 |
| Middle 50% of LOBEF reactions | -0.05% to +3.13% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 50 |
Half of all LOBE SCIENCES LTD news events land between -0.05% and +3.13% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when LOBEF moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LOBEF's baseline. Nothing else.
Recent LOBEF events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Lobe Sciences Appoints Annette Grimaldi, Former Head of Life Sciences Investment Banking at BMO Capital Markets, to Board of Directors | Press release | ACCESS Newswire | +0.00% | -4.71% | |
| Lobe Sciences Announces Proposed Capital Markets Initiatives to Support Planned Growth | Press release | ACCESS Newswire | +0.00% | +34.87% | |
| Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit | Press release | ACCESS Newswire | +0.00% | -5.75% | |
| Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement | Press release | ACCESS Newswire | +0.00% | +9.20% | |
| Lobe Sciences Expands Leadership Team with New CFO Appointment | Press release | ACCESS Newswire | -17.88% | -1.28% | |
| Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement | Press release | ACCESS Newswire | +0.00% | -3.07% | |
| Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement | Press release | ACCESS Newswire | +0.00% | +11.58% | |
| Lobe Sciences Reports Third Quarter 2026 Financial Results | Press release | ACCESS Newswire | +1.04% | +10.66% | |
| Lobe Sciences Ltd. Announces Non-Brokered Private Placement | Press release | ACCESS Newswire | — | — | |
| Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders | Press release | ACCESS Newswire | -10.62% | -0.95% | |
| Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026 | Press release | ACCESS Newswire | -10.21% | +10.35% | |
| Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares | Press release | ACCESS Newswire | +0.00% | +17.98% | |
| Lobe Sciences Announces Proposed Shares for Debt Transaction | Press release | ACCESS Newswire | +21.99% | +0.00% | |
| Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York | Press release | ACCESS Newswire | +0.00% | +0.43% | |
| Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress | Press release | ACCESS Newswire | +0.00% | -4.21% | |
| Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders | Press release | ACCESS Newswire | +33.16% | +42.39% | |
| Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services | Press release | ACCESS Newswire | +0.00% | +40.39% | |
| Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update | Press release | ACCESS Newswire | +40.11% | +30.10% | |
| Lobe Sciences Ltd. Announces Non-Brokered Private Placement | Press release | ACCESS Newswire | +0.00% | +29.91% | |
| Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update | Press release | ACCESS Newswire | -0.52% | +2.34% | |
| Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer | Press release | ACCESS Newswire | — | — | |
| Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences | Press release | ACCESS Newswire | — | — | |
| Lobe Sciences Reports First Quarter 2026 Results and Highlights | Press release | ACCESS Newswire | +13.82% | -2.25% | |
| Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors | Press release | ACCESS Newswire | +0.00% | -2.86% | |
| Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy | Press release | ACCESS Newswire | +0.00% | +13.64% | |
| Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition | Press release | ACCESS Newswire | +0.00% | +8.58% | |
| Lobe Sciences Completes Debt Settlement to Improve Balance Sheet | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| Lobe Sciences Improves Balance Sheet | Press release | ACCESS Newswire | +0.00% | +36.52% | |
| Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors | Press release | ACCESS Newswire | +0.00% | -0.61% | |
| Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025 | Press release | ACCESS Newswire | +3.33% | +15.33% | |
| Lobe Sciences Announces the Closing of the Previously Announced Private Placement | Press release | ACCESS Newswire | +0.00% | +3.25% | |
| Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes | Press release | ACCESS Newswire | +0.00% | — | |
| Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory | Press release | ACCESS Newswire | +0.00% | — | |
| Lobe Sciences Ltd. Announces Debt Settlement | Press release | ACCESS Newswire | +0.00% | +0.72% | |
| Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease | Press release | ACCESS Newswire | +4.35% | +17.39% | |
| Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals | Press release | ACCESS Newswire | +0.00% | +31.41% | |
| Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth | Press release | ACCESS Newswire | +0.00% | -1.67% | |
| Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM) | Press release | ACCESS Newswire | +0.00% | -14.29% | |
| Lobe Sciences Provides Corporate Update | Press release | ACCESS Newswire | +0.00% | -1.29% | |
| Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™ | Press release | Business Wire | +0.00% | +0.00% | |
| Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™ | Press release | Business Wire | +0.00% | -16.61% | |
| Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™ | Press release | Business Wire | +0.00% | +0.00% | |
| Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc. | Press release | Business Wire | +0.00% | +0.00% | |
| Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team | Press release | Business Wire | +0.00% | +13.21% | |
| Lobe Sciences Announces Update | Press release | Business Wire | +0.00% | +0.00% | |
| Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise | Press release | Business Wire | +4.00% | +29.33% | |
| Lobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors | Press release | Business Wire | +0.00% | +13.33% | |
| Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors | Press release | Business Wire | +0.00% | +1.00% | |
| Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders | Press release | Business Wire | +0.00% | +3.15% | |
| Lobe Sciences Provides Company Review of 2023 | Press release | Business Wire | +0.00% | +0.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LOBEF section they belong to.
Where else LOBEF is measured.
LOBEF earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is LOBE SCIENCES LTD's median reaction calculated?
Every labeled LOBEF news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 50 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 30% of LOBEF's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LOBEF's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.